Daiichi Sankyo to Acquire Coherus Oncology
Ticker: CHRS · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1512762
Sentiment: neutral
Topics: acquisition, merger, definitive-agreement
Related Tickers: CPRX
TL;DR
Daiichi Sankyo is buying Coherus Oncology, deal expected to close Q4 2025.
AI Summary
Coherus Oncology, Inc. announced on September 5, 2025, that it has entered into a definitive agreement to be acquired by a subsidiary of Daiichi Sankyo Company, Limited. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions. This acquisition marks a significant development for Coherus Oncology, as it transitions from a commercial-stage biopharmaceutical company to becoming part of a larger global healthcare organization.
Why It Matters
This acquisition by Daiichi Sankyo could lead to expanded resources and market reach for Coherus Oncology's products, potentially impacting patient access and future drug development.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a degree of uncertainty until the deal is finalized.
Key Players & Entities
- Coherus Oncology, Inc. (company) — Company filing the report and being acquired
- Daiichi Sankyo Company, Limited (company) — Acquiring company
- September 5, 2025 (date) — Date of the definitive agreement
- fourth quarter of 2025 (date) — Expected closing period for the acquisition
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing announces the definitive agreement for the acquisition of Coherus Oncology, Inc. by a subsidiary of Daiichi Sankyo Company, Limited.
Who is acquiring Coherus Oncology, Inc.?
A subsidiary of Daiichi Sankyo Company, Limited is acquiring Coherus Oncology, Inc.
When was the definitive agreement for the acquisition signed?
The definitive agreement was entered into on September 5, 2025.
When is the acquisition expected to close?
The acquisition is expected to close in the fourth quarter of 2025.
Are there any conditions to the closing of the acquisition?
Yes, the acquisition is subject to customary closing conditions.
Filing Stats: 533 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2025-09-08 09:54:50
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share CHRS The Nasdaq
- $1.00 — Company's common stock had closed below $1.00 per share, the minimum closing bid pric
Filing Documents
- chrs-20250905x8k.htm (8-K) — 36KB
- 0001558370-25-011911.txt ( ) — 154KB
- chrs-20250905.xsd (EX-101.SCH) — 4KB
- chrs-20250905_def.xml (EX-101.DEF) — 4KB
- chrs-20250905_lab.xml (EX-101.LAB) — 17KB
- chrs-20250905_pre.xml (EX-101.PRE) — 11KB
- chrs-20250905x8k_htm.xml (XML) — 5KB
01. Other Events
Item 8.01. Other Events As previously disclosed, on June 30, 2025, Coherus Oncology, Inc. (the "Company") received a deficiency notice (the "Notice") from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, for the last 30 consecutive business days, the bid price for the Company's common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq. The Company had a period of 180 calendar days, or until December 29, 2025, to regain compliance with the rule referred to in this paragraph. On September 5, 2025, the Company received a letter from Nasdaq notifying the Company that the Staff had determined that the closing price of the Company's common stock was $1.00 or greater for the requisite period of time and that the Company had regained compliance with Listing Rule 5550(a)(2) and that the matter was now closed. The Company is now in full compliance with all continued listing standards of the Nasdaq Global Market.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 8, 2025 COHERUS ONCOLOGY, INC. By: /s/ Dennis M. Lanfear Name: Dennis M. Lanfear Title: Chief Executive Officer